Atossa Genetics opens enrollment in mid-stage study of Endoxifen in breast cancer; shares up 5% premarket – Atossa Genetics, Inc. (NASDAQ:ATOS)

KeepHealthCare.ORG – Atossa Genetics opens enrollment in mid-stage study of Endoxifen in breast cancer; shares up 5% premarket – Atossa Genetics, Inc. (NASDAQ:ATOS) Thinly traded nano cap Atossa Genetics (NASDAQ:ATOS) Continue reading

Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density Nasdaq:ATOS

KeepHealthCare.ORG – Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density Nasdaq:ATOS SEATTLE, June 26, 2018 (GLOBE NEWSWIRE) — Atossa Genetics Inc. (ATOS) (“Atossa” Continue reading

Men’s testosterone levels determined by childhood conditions not genetics, study claims

KeepHealthCare.ORG – Men’s testosterone levels determined by childhood conditions not genetics, study claims A man’s testosterone levels are largely determined by his childhood environment rather than by genetics, new research Continue reading

Myriad Genetics Presents Second Pivotal Validation Study for riskScore™ Test at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

KeepHealthCare.ORG – Myriad Genetics Presents Second Pivotal Validation Study for riskScore™ Test at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Graph 1: Breast Cancer Risk Profile of Continue reading

Atossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study Nasdaq:ATOS

KeepHealthCare.ORG – Atossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study Nasdaq:ATOS SEATTLE, April 30, 2018 (GLOBE NEWSWIRE) — Atossa Genetics Inc. (Nasdaq:ATOS) Continue reading